To mark the 10th anniversary of the United Nation’s ‘International Day of Women and Girls in Science’ on February 11th, 2025 - AMSBIO has interviewed Dr Zoe Hewitt, an expert in cell and gene therapy manufacturing, and co-founder of Regen CTC*.
We are seeking a talented Data Scientist to work on an exciting project for the development of Digital Twins for rare disease. You will work within a multidisciplinary project team, across the Open Targets, BioModels and Petsalaki research groups at the EMBL European Bioinformatics Institute (EMBL-EBI). This project is funded through the Chan Zuckerberg Initiative with a strong emphasis on making datasets and models open source where possible.
Learn to Discover (L2D) is a cutting edge online training course in Python programming, data science and machine learning, tailored for health, disease and bioscience. L2D is accredited for CPD purposes by the Royal College of Physicians and the Royal Society of Biology and was developed at University College London.
To register your interest, please contact: [email protected]
Learn to Discover (L2D) is a cutting edge online training course in Python programming, data science and machine learning, tailored for health, disease and bioscience. L2D is accredited for CPD purposes by the Royal College of Physicians and the Royal Society of Biology and was developed at University College London.
To register your interest, please contact [email protected]
Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer Group and Novo Nordisk’s 2025 Golden Ticket Programme.
The 2025 Golden Ticket Programme was open to early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases, rare blood and rare endocrine disorders, with robust research plans and potential for successful research development.
London, February 11, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (“Bausch Health”) and is pleased to announce the placement of Jonathan Sadeh M.D., M.Sc.,as Executive Vice President, Chief Medical Officer and Head of R&D.
Job type: 1.5-year fixed term contract
Location: Oxford
Company: OMass Therapeutics
Right to work: You must have the right to work in the UK
Application deadline: 28th February 2025
Application submission: CV and cover letter via our website www.omass.com/working-here/
Expanded team to support development and commercialisation of precision antibiotics to help overcome antimicrobial resistance
Role Summary
We are looking for a strategic and results-driven Business Development Manager to lead the expansion of our business in the biotechnology sectors. This role is ideal for an individual with deep industry knowledge, a strong network, and a passion for driving business growth. The successful candidate will be responsible for identifying new opportunities, developing strategic partnerships, and increasing the company’s visibility across global markets.